Institute of Pharmaceutical Innovation, School of Pharmacy, University of Bradford, Bradford, BD7 1DP, UK.
AAPS PharmSciTech. 2010 Sep;11(3):1147-51. doi: 10.1208/s12249-010-9486-9. Epub 2010 Jul 24.
The aim of this work was to evaluate the in vitro performance of a nebulized nanoemulsion formulation which had been optimised previously. To do so, a transparent nanoemulsion preparation containing 1.5 mg/ml of budesonide was prepared and diluted to achieve concentrations of 250 and 500 μg/ml budesonide. The in vitro characteristics of the diluted nanoemulsions were then compared with the commercially available suspension of budesonide (Pulmicort Respules®) when nebulized using a jet and a vibrating mesh nebulizer. A smaller MMAD with improved aerosol output was observed in the nanoemulsion preparations compared with the corresponding suspension formulations indicating an improved in vitro performance for the nanoemulsion-based preparations.
本工作旨在评估先前优化的雾化纳米乳液制剂的体外性能。为此，制备了一种含有 1.5mg/ml 布地奈德的透明纳米乳液制剂，并将其稀释至布地奈德浓度为 250μg/ml 和 500μg/ml。然后，当使用射流和振动网孔雾化器雾化时，将稀释的纳米乳液的体外特性与市售的布地奈德混悬剂（Pulmicort Respules®）进行比较。与相应的混悬剂制剂相比，纳米乳液制剂的 MMAD 更小，气溶胶输出得到改善，表明基于纳米乳液的制剂具有更好的体外性能。
